about RenalytixAI

RenalytixAI is a developer of artificial intelligence (AI) enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally.  RenalytixAI’s solutions are being designed to make significant improvements in kidney disease risk assessment, clinical care and patient stratification for drug clinical trials.

RenalytixAI’s technology platform will draw from distinct sources of patient data, including large electronic health records, predictive blood-based biomarkers and other genomic information for analysis by learning computer algorithms. RenalytixAI intends to build a deep, unique pool of kidney disease-related data for different AI-enabled applications designed to improve predictive capability and clinical utility over time.

In 2019, RenalytixAI expects to launch KidneyIntelXTM, an AI-enabled, clinical-laboratory based solution intended to support physician decision making by improving identification, prediction, and risk stratification of patients with progressive kidney disease.

RenalytixAI considers there to be a significant opportunity to deliver quality-assured, regulated, AI-driven product for the chronic kidney disease (CKD) market.

A costly disease

The International Society of Nephrology estimates that over 850 million people worldwide have some form of kidney disease, approximately twice that of diabetes (422 million) and 20 times more than cancer.  By this estimate, kidney disease affects 10.4% of men and 11.8% of women worldwide.

In the US, CKD affects over 40 million adults and kills more people than breast or prostate cancer. Commonly referred to as a “silent disease” kidney disease is often asymptomatic until a majority of kidney function has been lost.  As a result, CKD is associated with significant morbidity, mortality and healthcare costs.

It is estimated that a third of adults in the US are at risk of kidney disease. This risk is greatest for those suffering from diabetes, high blood pressure, heart disease and obesity. Studies have also shown that ethnicity is a determining factor, with African Americans and Hispanic populations deemed most at risk.

latest News

07Jun

Positive results from FractalDx study published

Renalytix AI plc announces announces positive study results have been published in the Journal of Clinical Investigation (JCI) Insight... Read More →
04Jun

Commercial scale manufacturing milestone for KidneyIntelX™ test materials

Renalytix AI plc announces announces that its in-vitro diagnostic manufacturing programme has reached a critical development milestone for the production materials used to measure blood-based.. Read More →
28May

New York State Department of Health issues CLIA Certificate Number for Renalytix Lab

RenalytixAI announces announces that the New York State Department of Health has issued a Clinical Laboratory Improvement Amendment (CLIA) .. Read More →